New insights into METTL14’s role in pancreatic alpha cell identity and plasticity

A study in Nature Metabolism reveals that METTL14-driven m6A RNA modification influences glucagon secretion, cell identity, and lineage shifts in pancreatic alpha cells, with implications for diabetes treatment.

METTL14 helps drive amino acid-stimulated glucagon release in pancreatic alpha cells, according to a study in Nature Metabolism that also links the RNA-modifying enzyme to cell identity, lineage plasticity and beta-cell expansion.

The researchers began by reanalysing human pancreatic single-cell data and found that alpha cells carry high levels of several m6A RNA modification proteins. They then showed in mouse alpha cells that low glucose and amino acids such as arginine and glutamine raised METTL14 levels, while insulin and palmitate reduced them. In parallel, total m6A RNA marks rose when glucose was low or amino acids were added, suggesting that metabolic signals which promote glucagon release also boost the cell’s m6A machinery.

When METTL14 was reduced in alpha-cell models, arginine-triggered glucagon secretion fell away even though glucagon stores remained largely intact. In mice engineered to lose Mettl14 specifically in alpha cells, fasting glucagon and glucose were lower, and the normal glucagon surge after arginine was blunted in both males and females. Unexpectedly, the animals also showed higher insulin levels, and isolated islets from the knockout mice secreted more insulin under high glucose. The study authors interpret this as evidence that METTL14 normally supports alpha-cell hormone output while helping restrain a shift towards beta-cell-like behaviour.

That shift became more visible in the pancreas itself. The knockout mice had less alpha-cell mass, more beta-cell mass and more lineage-traced cells that co-expressed alpha- and beta-cell markers, pointing to alpha-to-beta transdifferentiation. Proliferation rates in alpha cells did not fall, but beta-cell proliferation rose, suggesting that the expanded beta-cell pool came from both conversion and growth. Single-nucleus RNA sequencing then identified a distinct alpha-cell state in the knockout animals, marked by loss of classic alpha-cell genes, activation of chromatin and cell-cycle programmes, and gain of progenitor-like and beta-cell-associated features.

At the molecular level, the paper traces much of this effect to YY1, a transcription factor that emerged as a METTL14-sensitive target in alpha cells. Loss of METTL14 reduced m6A on Yy1 transcripts and made the message more stable through the m6A reader YTHDF2, increasing YY1 protein. Raising YY1 levels in alpha cells altered signalling linked to insulin, mTOR and MAPK pathways, while also lowering key alpha-cell identity factors such as PAX6 and MAFB. The authors say this places YY1 downstream of METTL14 as part of a regulatory circuit that helps maintain alpha-cell identity.

Taken together, the study suggests that m6A RNA marking is not just a background epigenetic feature in pancreatic islets but a metabolic sensor that shapes whether alpha cells stay committed or drift towards other endocrine fates. The work adds to evidence that RNA modification can influence both hormone secretion and cell plasticity, with potential implications for diabetes research and for strategies aimed at reprogramming islet cells.